{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:06:40Z","timestamp":1786421200913,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018036","name":"Nippon Shinyaku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) is a recently identified clonal disorder caused by somatic\n                    <jats:italic>UBA1<\/jats:italic>\n                    mutations in hematopoietic stem cells, leading to bone marrow failure (BMF) and systemic inflammation. We screened 1771 patients with BMF who underwent unrelated hematopoietic cell transplantation in Japan between 1995 and 2020 using multitarget real-time PCR. The diagnoses included myelodysplastic syndrome (MDS,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091139), myeloproliferative neoplasms (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009125), plasma cell neoplasms (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200923), acquired BMF (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009395), and congenital BMF (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200989). Pathogenic\n                    <jats:italic>UBA1<\/jats:italic>\n                    mutations were detected in two male patients with MDS (aged 48 and 63\u00a0years), corresponding to a prevalence of 0.11% in the overall cohort and 0.18% in MDS cases; an additional 70-year-old male was diagnosed outside of the cohort. All three underwent unrelated bone marrow transplantation following fludarabine and busulfan-based conditioning. The first and third patients died of idiopathic pneumonia syndrome 5 and 28\u00a0months after transplantation. In the third patient,\n                    <jats:italic>UBA1<\/jats:italic>\n                    -mutant cells persisted at low frequency in skin graft-versus-host disease tissue despite clearance from his blood. The second patient survived without relapse or graft-versus-host disease at 28\u00a0months. Although VEXAS syndrome is rare among unrelated HCT recipients with malignant and non-malignant BMF in the historical cohort, HCT is positioned as a potentially curative, yet high-risk strategy. Additional studies are essential to refine patient selection, optimize transplant timing, and improve management strategies to mitigate risk and enhance survival. Therefore, the role of tissue-residual\n                    <jats:italic>UBA1<\/jats:italic>\n                    -mutant clones in post-transplant complications warrants further investigation.\n                  <\/jats:p>","DOI":"10.1007\/s10238-025-01832-7","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T15:49:44Z","timestamp":1755877784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence and outcome of VEXAS syndrome in unrelated hematopoietic cell transplantation for bone marrow failure"],"prefix":"10.1007","volume":"25","author":[{"given":"Yoshitaka","family":"Zaimoku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Imi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Hatada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Mizumaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Mura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miku","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Fushida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Mizuguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Hosomichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Japanese Society of Transplantation and Cellular Therapy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"27","key":"1832_CR1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383(27):2628\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2026834.","journal-title":"N Engl J Med"},{"key":"1832_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03623-9","author":"R Molteni","year":"2025","unstructured":"Molteni R, Fiumara M, Campochiaro C, Alfieri R, Pacini G, Licari E, et al. Mechanisms of hematopoietic clonal dominance in VEXAS syndrome. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03623-9.","journal-title":"Nat Med"},{"key":"1832_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425\u201379. https:\/\/doi.org\/10.1146\/annurev.biochem.67.1.425.","journal-title":"Annu Rev Biochem"},{"key":"1832_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.biochem.70.1.503","volume":"70","author":"CM Pickart","year":"2001","unstructured":"Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503\u201333. https:\/\/doi.org\/10.1146\/annurev.biochem.70.1.503.","journal-title":"Annu Rev Biochem"},{"issue":"13","key":"1832_CR5","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/blood.2022016985","volume":"140","author":"MA Ferrada","year":"2022","unstructured":"Ferrada MA, Savic S, Cardona DO, Collins JC, Alessi H, Gutierrez-Rodrigues F, et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood. 2022;140(13):1496\u2013506. https:\/\/doi.org\/10.1182\/blood.2022016985.","journal-title":"Blood"},{"issue":"8","key":"1832_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101160","volume":"4","author":"Z Wu","year":"2023","unstructured":"Wu Z, Gao S, Gao Q, Patel BA, Groarke EM, Feng X, et al. Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS. Cell Rep Med. 2023;4(8): 101160. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101160.","journal-title":"Cell Rep Med"},{"issue":"10","key":"1832_CR7","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/rheumatology\/keae123","volume":"63","author":"R Echerbault","year":"2024","unstructured":"Echerbault R, Bourguiba R, Georgin-Lavialle S, Lavigne C, Ravaiau C, Lacombe V. Comparing clinical features between males and females with VEXAS syndrome: data from literature analysis of patient reports. Rheumatology (Oxford). 2024;63(10):2694\u2013700. https:\/\/doi.org\/10.1093\/rheumatology\/keae123.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1832_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1182\/blood.2022018774","volume":"142","author":"F Gutierrez-Rodrigues","year":"2023","unstructured":"Gutierrez-Rodrigues F, Kusne Y, Fernandez J, Lasho T, Shalhoub R, Ma X, et al. Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood. 2023;142(3):244\u201359. https:\/\/doi.org\/10.1182\/blood.2022018774.","journal-title":"Blood"},{"issue":"4","key":"1832_CR9","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s12185-023-03598-8","volume":"118","author":"H Kunimoto","year":"2023","unstructured":"Kunimoto H, Miura A, Maeda A, Tsuchida N, Uchiyama Y, Kunishita Y, et al. Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome. Int J Hematol. 2023;118(4):494\u2013502. https:\/\/doi.org\/10.1007\/s12185-023-03598-8.","journal-title":"Int J Hematol"},{"issue":"11","key":"1832_CR10","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1182\/blood.2023023723","volume":"144","author":"M Sirenko","year":"2024","unstructured":"Sirenko M, Bernard E, Creignou M, Domenico D, Farina A, Arango Ossa JE, et al. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes. Blood. 2024;144(11):1221\u20139. https:\/\/doi.org\/10.1182\/blood.2023023723.","journal-title":"Blood"},{"issue":"4","key":"1832_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jama.2022.24836","volume":"329","author":"DB Beck","year":"2023","unstructured":"Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, et al. Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population. JAMA. 2023;329(4):318\u201324. https:\/\/doi.org\/10.1001\/jama.2022.24836.","journal-title":"JAMA"},{"issue":"5","key":"1832_CR12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41375-023-01857-5","volume":"37","author":"M Sakuma","year":"2023","unstructured":"Sakuma M, Blombery P, Meggendorfer M, Haferlach C, Lindauer M, Martens UM, et al. Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies. Leukemia. 2023;37(5):1080\u201391. https:\/\/doi.org\/10.1038\/s41375-023-01857-5.","journal-title":"Leukemia"},{"issue":"26","key":"1832_CR13","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1182\/blood.2020010177","volume":"137","author":"E Bourbon","year":"2021","unstructured":"Bourbon E, Heiblig M, Gerfaud Valentin M, Barba T, Durel CA, Lega JC, et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood. 2021;137(26):3682\u20134. https:\/\/doi.org\/10.1182\/blood.2020010177.","journal-title":"Blood"},{"issue":"8","key":"1832_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood.2022016642","volume":"140","author":"M Heiblig","year":"2022","unstructured":"Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, M\u00e9kinian A, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022;140(8):927\u201331. https:\/\/doi.org\/10.1182\/blood.2022016642.","journal-title":"Blood"},{"issue":"3","key":"1832_CR15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","volume":"186","author":"S Georgin-Lavialle","year":"2022","unstructured":"Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2022;186(3):564\u201374. https:\/\/doi.org\/10.1111\/bjd.20805.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1832_CR16","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/ard-2024-225640","volume":"83","author":"J Hadjadj","year":"2024","unstructured":"Hadjadj J, Nguyen Y, Mouloudj D, Bourguiba R, Heiblig M, Aloui H, et al. Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Ann Rheum Dis. 2024;83(10):1358\u201367. https:\/\/doi.org\/10.1136\/ard-2024-225640.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1832_CR17","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1093\/rheumatology\/kead240","volume":"62","author":"Z Boyadzhieva","year":"2023","unstructured":"Boyadzhieva Z, Ruffer N, K\u00f6tter I, Krusche M. How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology (Oxford). 2023;62(11):3518\u201325. https:\/\/doi.org\/10.1093\/rheumatology\/kead240.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1832_CR18","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S2665-9913(25)00034-7","volume":"7","author":"A Al-Hakim","year":"2025","unstructured":"Al-Hakim A, Trikha R, Phyu Htut EE, Chowdhury O, MacLennan CA, Chee A, et al. Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study. Lancet Rheumatol. 2025;7(7):e472\u201384. https:\/\/doi.org\/10.1016\/S2665-9913(25)00034-7.","journal-title":"Lancet Rheumatol"},{"key":"1832_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.021","author":"BA Turturice","year":"2025","unstructured":"Turturice BA, Fike A, Patel BA, Groarke EM, Gutierrez-Rodriguez F, Stonick K, et al. Disease trajectories and glucocorticoid exposure in VEXAS syndrome treated with cytokine-directed therapies. Ann Rheum Dis. 2025. https:\/\/doi.org\/10.1016\/j.ard.2025.05.021.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1832_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000661","volume":"5","author":"MHGP Raaijmakers","year":"2021","unstructured":"Raaijmakers MHGP, Hermans M, Aalbers A, Rijken M, Dalm VASH, van Daele P, et al. Azacytidine treatment for VEXAS syndrome. Hemasphere. 2021;5(12): e661. https:\/\/doi.org\/10.1097\/HS9.0000000000000661.","journal-title":"Hemasphere"},{"issue":"11","key":"1832_CR21","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","volume":"36","author":"A Mekinian","year":"2022","unstructured":"Mekinian A, Zhao LP, Chevret S, Desseaux K, Pascal L, Comont T, et al. A phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML. Leukemia. 2022;36(11):2739\u201342. https:\/\/doi.org\/10.1038\/s41375-022-01698-8.","journal-title":"Leukemia"},{"issue":"4","key":"1832_CR22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjh.17893","volume":"196","author":"T Comont","year":"2022","unstructured":"Comont T, Heiblig M, Rivi\u00e8re E, Terriou L, Rossignol J, Bouscary D, et al. Azacitidine for patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol. 2022;196(4):969\u201374. https:\/\/doi.org\/10.1111\/bjh.17893.","journal-title":"Br J Haematol"},{"issue":"6","key":"1832_CR23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s12185-023-03532-y","volume":"117","author":"A Kataoka","year":"2023","unstructured":"Kataoka A, Mizumoto C, Kanda J, Iwasaki M, Sakurada M, Oka T, et al. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome. Int J Hematol. 2023;117(6):919\u201324. https:\/\/doi.org\/10.1007\/s12185-023-03532-y.","journal-title":"Int J Hematol"},{"issue":"8","key":"1832_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.129","volume":"8","author":"AM Aalbers","year":"2024","unstructured":"Aalbers AM, van Daele PLA, Dalm VASH, Valk PJM, Raaijmakers MHGP. Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome. Hemasphere. 2024;8(8): e129. https:\/\/doi.org\/10.1002\/hem3.129.","journal-title":"Hemasphere"},{"issue":"3","key":"1832_CR25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00277-023-05611-w","volume":"103","author":"K Sockel","year":"2024","unstructured":"Sockel K, G\u00f6tze K, Ganster C, Bill M, Georgi JA, Balaian E, et al. VEXAS syndrome: complete molecular remission after hypomethylating therapy. Ann Hematol. 2024;103(3):993\u20137. https:\/\/doi.org\/10.1007\/s00277-023-05611-w.","journal-title":"Ann Hematol"},{"issue":"10","key":"1832_CR26","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.3324\/haematol.2024.285519","volume":"109","author":"R Trikha","year":"2024","unstructured":"Trikha R, Kong KL, Galloway J, Basu TN, Quek L, Wilson J, et al. De-escalation of corticosteroids and clonal remission in UBA1 mutation-driven VEXAS syndrome with 5-azacytidine. Haematologica. 2024;109(10):3431\u20134. https:\/\/doi.org\/10.3324\/haematol.2024.285519.","journal-title":"Haematologica"},{"issue":"2","key":"1832_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/bjh.19953","volume":"206","author":"JR \u00c1lamo","year":"2025","unstructured":"\u00c1lamo JR, Torres LM, Casta\u00f1o-D\u00edez S, Mensa-Vilar\u00f3 A, M\u00f3nica L\u00f3pez-Guerra M, Zugasti I, et al. Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics. Br J Haematol. 2025;206(2):565\u201375. https:\/\/doi.org\/10.1111\/bjh.19953.","journal-title":"Br J Haematol"},{"key":"1832_CR28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028133","author":"V Jachiet","year":"2025","unstructured":"Jachiet V, Kosmider O, Beydon M, Hadjadj J, Zhao LP, Grobost V, et al. Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2024028133.","journal-title":"Blood"},{"issue":"6","key":"1832_CR29","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/bjh.20067","volume":"206","author":"M Heiblig","year":"2025","unstructured":"Heiblig M, Plesa A, Tantot J, Jamilloux Y, Labussi\u00e8re-Wallet H, Sujobert P. Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: a single-centre experience. Br J Haematol. 2025;206(6):1683\u20138. https:\/\/doi.org\/10.1111\/bjh.20067.","journal-title":"Br J Haematol"},{"issue":"3","key":"1832_CR30","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","volume":"6","author":"A Diarra","year":"2022","unstructured":"Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L, et al. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv. 2022;6(3):998\u20131003. https:\/\/doi.org\/10.1182\/bloodadvances.2021004749.","journal-title":"Blood Adv"},{"issue":"5","key":"1832_CR31","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bjh.18488","volume":"199","author":"A Al-Hakim","year":"2022","unstructured":"Al-Hakim A, Poulter JA, Mahmoud D, Rose AMS, Elcombe S, Lachmann H, et al. Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience. Br J Haematol. 2022;199(5):777\u201381. https:\/\/doi.org\/10.1111\/bjh.18488.","journal-title":"Br J Haematol"},{"issue":"2","key":"1832_CR32","doi-asserted-by":"publisher","first-page":"E28","DOI":"10.1002\/ajh.26786","volume":"98","author":"AA Mangaonkar","year":"2023","unstructured":"Mangaonkar AA, Langer KJ, Lasho TL, Finke C, Litzow MR, Hogan WJ, et al. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: data from a prospective series of patients. Am J Hematol. 2023;98(2):E28\u201331. https:\/\/doi.org\/10.1002\/ajh.26786.","journal-title":"Am J Hematol"},{"issue":"2","key":"1832_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41409-021-01544-y","volume":"57","author":"M Loschi","year":"2022","unstructured":"Loschi M, Roux C, Sudaka I, Ferrero-Vacher C, Marceau-Renaut A, Duployez N, et al. Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report. Bone Marrow Transplant. 2022;57(2):315\u20138. https:\/\/doi.org\/10.1038\/s41409-021-01544-y.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1832_CR34","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1111\/bjh.18424","volume":"199","author":"N van Leeuwen-Kerkhoff","year":"2022","unstructured":"van Leeuwen-Kerkhoff N, de Witte MA, Heijstek MW, Leavis HL. Case report: Up-front allogeneic stem cell transplantation in a patient with the VEXAS syndrome. Br J Haematol. 2022;199(3):e12\u20135. https:\/\/doi.org\/10.1111\/bjh.18424.","journal-title":"Br J Haematol"},{"issue":"12","key":"1832_CR35","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard-2023-224460","volume":"82","author":"JM Mascaro","year":"2023","unstructured":"Mascaro JM, Rodriguez-Pinto I, Poza G, Mensa-Vilaro A, Fernandez-Martin J, Caminal-Montero L, et al. Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about. Ann Rheum Dis. 2023;82(12):1594\u2013605. https:\/\/doi.org\/10.1136\/ard-2023-224460.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1832_CR36","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1182\/bloodadvances.2023012478","volume":"8","author":"C Gurnari","year":"2024","unstructured":"Gurnari C, Koster L, Baaij L, Heiblig M, Yakoub-Agha I, Collin M, et al. Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT. Blood Adv. 2024;8(6):1444\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2023012478.","journal-title":"Blood Adv"},{"issue":"3","key":"1832_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1532\/IJH97.06239","volume":"86","author":"Y Atsuta","year":"2007","unstructured":"Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system. Int J Hematol. 2007;86(3):269\u201374. https:\/\/doi.org\/10.1532\/IJH97.06239.","journal-title":"Int J Hematol"},{"issue":"8","key":"1832_CR38","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/annrheumdis-2021-220089","volume":"80","author":"N Tsuchida","year":"2021","unstructured":"Tsuchida N, Kunishita Y, Uchiyama Y, Kirino Y, Enaka M, Yamaguchi Y, et al. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis. 2021;80(8):1057\u201361. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220089.","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"1832_CR39","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","volume":"129","author":"T Yoshizato","year":"2017","unstructured":"Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129(17):2347\u201358. https:\/\/doi.org\/10.1182\/blood-2016-12-754796.","journal-title":"Blood"},{"issue":"14","key":"1832_CR40","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1182\/bloodadvances.2022009564","volume":"7","author":"Y Nannya","year":"2023","unstructured":"Nannya Y, Tobiasson M, Sato S, Bernard E, Ohtake S, Takeda J, et al. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. Blood Adv. 2023;7(14):3624\u201336. https:\/\/doi.org\/10.1182\/bloodadvances.2022009564.","journal-title":"Blood Adv"},{"key":"1832_CR41","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2025 Apr 16. [cited 2025 Jun 14]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Data source(s): SEER Incidence Data, November 2024 Submission (1975\u20132022), SEER 21 registries. In."},{"issue":"8","key":"1832_CR42","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamadermatol.2024.1657","volume":"160","author":"IJ Tan","year":"2024","unstructured":"Tan IJ, Ferrada MA, Ahmad S, Fike A, Quinn KA, Groarke EM, et al. Skin manifestations of VEXAS syndrome and associated genotypes. JAMA Dermatol. 2024;160(8):822\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2024.1657.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1832_CR43","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/s41409-024-02375-3","volume":"59","author":"R Mohty","year":"2024","unstructured":"Mohty R, Reljic T, Abdel-Razeq N, Jamy O, Badar T, Kumar A, et al. Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysis. Bone Marrow Transplant. 2024;59(10):1423\u20137. https:\/\/doi.org\/10.1038\/s41409-024-02375-3.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"1832_CR44","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s10067-024-07160-7","volume":"43","author":"SB Ali","year":"2024","unstructured":"Ali SB, Gurnari C. Allogenic haematopoietic stem cell transplantation in VEXAS: a review of 33 patients. Clin Rheumatol. 2024;43(11):3565\u201375. https:\/\/doi.org\/10.1007\/s10067-024-07160-7.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"1832_CR45","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1007\/s00277-024-05942-2","volume":"103","author":"AL Dias","year":"2024","unstructured":"Dias AL, Groarke EM, Hickstein D, Patel B. Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome. Ann Hematol. 2024;103(11):4427\u201336. https:\/\/doi.org\/10.1007\/s00277-024-05942-2.","journal-title":"Ann Hematol"},{"issue":"3","key":"1832_CR46","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/ard-2023-224819","volume":"83","author":"B de Valence","year":"2024","unstructured":"de Valence B, Delaune M, Nguyen Y, Jachiet V, Heiblig M, Jean A, et al. Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry. Ann Rheum Dis. 2024;83(3):372\u201381. https:\/\/doi.org\/10.1136\/ard-2023-224819.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1832_CR47","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1038\/s41467-025-59890-0","volume":"16","author":"H Mizumaki","year":"2025","unstructured":"Mizumaki H, Gao S, Wu Z, Gutierrez-Rodrigues F, Bissa M, Feng X, et al. In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome. Nat Commun. 2025;16(1):4690. https:\/\/doi.org\/10.1038\/s41467-025-59890-0.","journal-title":"Nat Commun"},{"issue":"7","key":"1832_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae405","volume":"11","author":"M Czech","year":"2024","unstructured":"Czech M, Cuellar-Rodriguez J, Patel BA, Groarke EM, Cowen EW, Turturice B, et al. Opportunistic infections, mortality risk, and prevention strategies in patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. Open Forum Infect Dis. 2024;11(7): ofae405. https:\/\/doi.org\/10.1093\/ofid\/ofae405.","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"1832_CR49","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1093\/rheumatology\/keab524","volume":"60","author":"M Templ\u00e9","year":"2021","unstructured":"Templ\u00e9 M, Duroyon E, Croizier C, Rossignol J, Huet T, Friedrich C, et al. Atypical splice-site mutations causing VEXAS syndrome. Rheumatology (Oxford). 2021;60(12):e435\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keab524.","journal-title":"Rheumatology (Oxford)"},{"issue":"26","key":"1832_CR50","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood.2020010286","volume":"137","author":"JA Poulter","year":"2021","unstructured":"Poulter JA, Collins JC, Cargo C, De Tute RM, Evans P, Ospina Cardona D, et al. Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood. 2021;137(26):3676\u201381. https:\/\/doi.org\/10.1182\/blood.2020010286.","journal-title":"Blood"},{"issue":"9","key":"1832_CR51","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1093\/rheumatology\/keab225","volume":"60","author":"A Oganesyan","year":"2021","unstructured":"Oganesyan A, Jachiet V, Chasset F, Hirsch P, Hage-Sleiman M, Fabiani B, et al. VEXAS syndrome: still expanding the clinical phenotype. Rheumatology (Oxford). 2021;60(9):e321\u20133. https:\/\/doi.org\/10.1093\/rheumatology\/keab225.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1832_CR52","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/art.42471","volume":"75","author":"B Stiburkova","year":"2023","unstructured":"Stiburkova B, Pavelcova K, Belickova M, Magaziner SJ, Collins JC, Werner A, et al. Novel somatic UBA1 variant in a patient with VEXAS syndrome. Arthritis Rheumatol. 2023;75(7):1285\u201390. https:\/\/doi.org\/10.1002\/art.42471.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1832_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000868","volume":"7","author":"A Faurel","year":"2023","unstructured":"Faurel A, Heiblig M, Kosmider O, Cornillon J, Boudou L, Guyotat D, et al. Recurrent mutations of the active adenylation domain of UBA1 in atypical form of VEXAS syndrome. Hemasphere. 2023;7(4): e868. https:\/\/doi.org\/10.1097\/HS9.0000000000000868.","journal-title":"Hemasphere"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01832-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01832-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01832-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:52:06Z","timestamp":1764917526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01832-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1832"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01832-7","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests. Y.Z. serves as an Associate Editor of Clinical and Experimental Medicine but was not involved in the review process of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"300"}}